A Response to: Letter to the Editor Regarding "Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain"

针对“Elranatamab 与现有疗法在治疗接受过三类抗癌药物治疗、复发和难治性多发性骨髓瘤患者（包括其他双特异性抗体和西班牙医生选择的治疗方案）中的成本效益”一文的回复